Get started
Work

385P Patient reported outcomes (PROs) analysis for patients with ROS1 fusion-positive (ROS1+) non-small cell lung cancer (NSCLC) receiving entrectinib in the global phase II STARTRK-2 study

Year: 2020
Type: article
DOI: 10.1016/j.annonc.2020.10.379
Authors: F. Barlesi, J. Wolf, M-J. Ahn, R.C. Doebele, L. Paz-Ares, C. Rolfo, S. Siena, T. Seto, Y. Ohe, S.H.I. Ou, M.G. Krebs, A. Kapre, E. Piault-Louis, S. McCallum, S. Osborne, A. Aziez, A. Drilon
Institutions: Centre National de la Recherche Scientifique, Inserm, Aix-Marseille Université, Centre de Recherche en Cancérologie de Marseille, University Hospital Cologne, Samsung Medical Center, Sungkyunkwan University, University of Colorado Anschutz, Spanish National Cancer Research Centre, Hospital Universitario 12 De Octubre, University of Maryland, Baltimore, University of Milan, Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda, National Hospital Organization Kyushu Cancer Center, National Cancer Center Hospital, University of California, Irvine, University of Manchester, The Christie NHS Foundation Trust, Genentech, F. Hoffmann-La Roche AG, Memorial Sloan Kettering Cancer Center
Language: English
Field: Medicine
Open Access status: bronze
Funders: Amgen, Eli Lilly and Company, Pfizer, AstraZeneca, Celgene, Merck KGaA, Taiho Pharmaceutical, Yuhan, Kyowa Hakko Kirin, Shionogi, Ono Pharmaceutical, Genentech, EMD Serono, Chugai Pharmaceutical, MSD K.K., Daiichi Sankyo Europe
OpenAlex ID: W3110505391
FWCI: 0.423
Cites: 2
Cited by: 3
Related to: 10